In vitro inhibitory and cytotoxic activity of MFM 501, a Novel codonopsinine derivative, against methicillin-resistant Staphylococcus aureus clinical isolates

28 new pyrrolidine types of compounds as analogues for natural polyhydroxy alkaloids of codonopsinine were evaluated for their anti-MRSA activity using MIC and MBC value determination assay against a panel of S. aureus isolates. One pyrrolidine compound, MFM 501, exhibited good inhibitory activity w...

Full description

Bibliographic Details
Main Authors: Hamzah, A.S (Author), Johari, S.A (Author), Mohammat, M.F (Author), Mohtar, M. (Author), Sahdan, R. (Author), Shaameri, Z. (Author), Syed Mohammad, S.A (Author)
Format: Article
Language:English
Published: Hindawi Publishing Corporation 2015
Subjects:
Online Access:View Fulltext in Publisher
View in Scopus
LEADER 03596nam a2200733Ia 4500
001 10.1155-2015-823829
008 220112s2015 CNT 000 0 und d
020 |a 23146133 (ISSN) 
245 1 0 |a In vitro inhibitory and cytotoxic activity of MFM 501, a Novel codonopsinine derivative, against methicillin-resistant Staphylococcus aureus clinical isolates 
260 0 |b Hindawi Publishing Corporation  |c 2015 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1155/2015/823829 
856 |z View in Scopus  |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924128813&doi=10.1155%2f2015%2f823829&partnerID=40&md5=00eb3281bef111e45d7999221e3e78a3 
520 3 |a 28 new pyrrolidine types of compounds as analogues for natural polyhydroxy alkaloids of codonopsinine were evaluated for their anti-MRSA activity using MIC and MBC value determination assay against a panel of S. aureus isolates. One pyrrolidine compound, MFM 501, exhibited good inhibitory activity with MIC value of 15.6 to 31.3 g/mL against 55 S. aureus isolates (43 MRSA and 12 MSSA isolates). The active compound also displayed MBC values between 250 and 500 g/mL against 58 S. aureus isolates (45 MRSA and 13 MSSA isolates) implying that MFM 501 has a bacteriostatic rather than bactericidal effect against both MRSA and MSSA isolates. In addition, MFM 501 showed no apparent cytotoxicity activity towards three normal cell lines (WRL-68, Vero, and 3T3) with IC50 values of >625 μg/mL. Selectivity index (SI) of MFM 501 gave a value of >10 suggesting that MFM 501 is significant and suitable for further in vivo investigations. These results suggested that synthetically derived intermediate compounds based on natural products may play an important role in the discovery of new anti-infective agents against MRSA. © 2015 Saiful Azmi Johari et al. 
650 0 4 |a alkaloid 
650 0 4 |a Alkaloids 
650 0 4 |a Anti-Bacterial Agents 
650 0 4 |a antibiotic agent 
650 0 4 |a antiinfective agent 
650 0 4 |a apoptosis 
650 0 4 |a Apoptosis 
650 0 4 |a Article 
650 0 4 |a bactericidal activity 
650 0 4 |a bacteriostasis 
650 0 4 |a bacterium isolation 
650 0 4 |a cell survival 
650 0 4 |a Cell Survival 
650 0 4 |a chemistry 
650 0 4 |a clinical evaluation 
650 0 4 |a codonopsinine 
650 0 4 |a controlled study 
650 0 4 |a cytology 
650 0 4 |a cytotoxicity 
650 0 4 |a dose response 
650 0 4 |a Dose-Response Relationship, Drug 
650 0 4 |a drug effects 
650 0 4 |a drug safety 
650 0 4 |a drug screening 
650 0 4 |a IC50 
650 0 4 |a in vitro study 
650 0 4 |a in vivo study 
650 0 4 |a methicillin resistant Staphylococcus aureus 
650 0 4 |a methicillin susceptible Staphylococcus aureus 
650 0 4 |a Methicillin-Resistant Staphylococcus aureus 
650 0 4 |a mfm 501 
650 0 4 |a microbial sensitivity test 
650 0 4 |a Microbial Sensitivity Tests 
650 0 4 |a minimum bactericidal concentration 
650 0 4 |a minimum inhibitory concentration 
650 0 4 |a nonhuman 
650 0 4 |a physiology 
650 0 4 |a pyrrolidine derivative 
650 0 4 |a Pyrrolidines 
650 0 4 |a reaction analysis 
650 0 4 |a Staphylococcus aureus 
650 0 4 |a structure activity relation 
650 0 4 |a unclassified drug 
700 1 0 |a Hamzah, A.S.  |e author 
700 1 0 |a Johari, S.A.  |e author 
700 1 0 |a Mohammat, M.F.  |e author 
700 1 0 |a Mohtar, M.  |e author 
700 1 0 |a Sahdan, R.  |e author 
700 1 0 |a Shaameri, Z.  |e author 
700 1 0 |a Syed Mohammad, S.A.  |e author 
773 |t BioMed Research International